Mustang Bio, Inc.
(NASDAQ : MBIO)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
BMYBristol-Myers Squibb Co.
2.06%63.701.4%$1705.23m
JNJJohnson & Johnson
-0.01%140.970.7%$887.68m
PFEPfizer Inc.
0.67%38.480.9%$748.16m
MRKMerck & Co., Inc.
0.56%89.480.7%$690.58m
ABBVAbbVie, Inc.
1.12%87.672.3%$630.85m
LLYEli Lilly & Co.
0.39%121.251.1%$359.02m
NVSNovartis AG
-0.40%92.670.2%$145.29m
AZNAstraZeneca Plc
-0.31%48.041.2%$139.30m
GSKGlaxoSmithKline Plc
-0.93%45.860.2%$134.68m
RETAReata Pharmaceuticals, Inc.
0.63%200.803.5%$133.40m
KRTXKaruna Therapeutics, Inc.
2.45%66.000.0%$101.36m
SNYSanofi
0.33%49.170.2%$100.39m
NVONovo Nordisk A/S
-0.69%56.470.1%$87.98m
ALLKAllakos, Inc.
1.26%122.790.0%$74.09m
FTSVForty Seven, Inc.
4.28%37.500.0%$44.08m

Company Profile

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of a broad range of proprietary chimeric antigen receptor engineered T cell (CAR T) immunotherapies and gene therapies. It develops CAR T and CRISPR/Cas9-enhanced CAR T therapies across multiple cancers, as well as lentiviral gene therapy for XSCID. The firm's products include MB-101 IL13Ra2-specific CAR, MB-102 CD123 CAR, MB-103 HER2 CAR, MB-104 CS1 CAR, MB-105 PSCA CAR, MB-106 CD20 CAR, MB-107 XSCID Gene Therapy and Oncolytic Virus (C134). The company was founded on March 13, 2015 and is headquartered in New York, NY.